Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 29, 2020
Daily News
September 29, 2020
- MHLW Pharma Bureau Seeks 13 Billion Yen for FY2021, Eyes Vaccine Quality Assurance Guidance in COVID-19 Quota
September 29, 2020
- MHLW Seeks Nearly 33 Trillion Yen in Unusual Budget Request for FY2021; COVID-19 Quota Yet to Come
September 29, 2020
- MHLW’s Health Policy Bureau Requests New Budgets to Forge Clinical Trial Network in Asia
September 29, 2020
- Coronavirus Panel OKs Interim Report on COVID-19 Vaccination, Sorts Out Roles of Central, Local Govts
September 29, 2020
- 2nd GPCR-Targeted Candidate Enters Clinic under Sosei/Pfizer’s Drug Discovery Alliance
September 29, 2020
- Otsuka Files Japan NDA for Atopic Dermatitis Drug Difamilast
September 29, 2020
- AbbVie Files New Dosage Forms for Skyrizi in Japan
September 29, 2020
- Approval Now in Hand, CureApp Looks at Collaborations with Drug Makers to Push Therapeutic Apps
September 29, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…